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Introduction: HIV/AIDS is a chronic disease; therefore, recognizing 
which factors favor adherence to antiretroviral treatment is necessary. 
Objective: To determine the association between adherence to 
antiretroviral treatment and depression, anxiety, perception of social 
support and sociodemographic variables in people living with HIV/
AIDS in Quindío, Colombia. 
Materials and methods: An observational, cross-sectional study was 
performed in an intentional sample of 70 adults, who were applied 
the Morisky-Green questionnaire, the Beck Depression Inventory, 
the Beck Anxiety Inventory, the Medical Outcomes Study (MOS) 
Social Support Survey, and a sociodemographic survey. Univariate 
and bivariate analyzes were performed by calculating the odds ratio 
to determine association (p<0.05). 
Results: 57.1% of the participants reported low adherence to treatment, 
30% had moderate or severe depressive symptoms, 71.4% scored 
minimal or mild anxiety levels, and 77.1% had a low perception of 
social support. A statistical association between depression (high levels 
tripled the risk of non-adherence) and self-report on how treatment 
is followed (excellent or good self-report increased by five times the 
probability of adherence) was found. 
Conclusion: Depression and self-report on compliance were associated 
with adherence to antiretroviral therapy. A comprehensive study on 
the perception of social support and cognitive variables, such as self-
efficacy and risk perception, is highly recommended for people living 
with HIV/AIDS.
Keywords: HIV; Antiretroviral Therapy Highly Active; Medication 
Adherence; Depression; Anxiety; Social Support (MeSH).
Cardona-Duque DV, Medina-Pérez OA, Herrera-Castaño SM, Orozco-
Gómez PA. Antiretroviral treatment adherence and associated factors in people 
living with HIV/aids in Quindío – Colombia. Rev. Fac. Med. 2017;65(3):403-
10. English. doi: http://dx.doi.org/10.15446/revfacmed.v65n3.55535.
| Resumen |
Introducción. El VIH/sida es una enfermedad crónica, por ello es 
necesario reconocer qué factores favorecen la adhesión al tratamiento 
antirretroviral. 
Objetivo. Determinar la asociación entre adhesión al tratamiento 
antirretroviral y depresión, ansiedad, percepción de apoyo social y 
variables sociodemográficas en personas viviendo con VIH/sida en 
Quindío, Colombia. 
Materiales y métodos. Se realizó un estudio observacional analítico 
de tipo transversal en una muestra intencional de 70 adultos, a quienes 
se les aplicó el cuestionario autorreferido de Morisky-Green, el 
Inventario de Depresión de Beck, el Inventario de Ansiedad de Beck, 
el cuestionario MOS (Medical Outcomes Study) de Apoyo Social y 
una encuesta sociodemográfica. Se realizaron análisis univariados y 
bivariados calculando Odds Ratio para determinar asociación (p<0.05). 
Resultados. 57.1% de los participantes reportó poca adhesión al 
tratamiento, 30% presentó síntomas depresivos moderados o graves, 
71.4% puntuó niveles mínimos o leves de ansiedad y 77.1% tuvo baja 
percepción de apoyo social. Se encontró asociación estadística entre 
depresión —niveles altos triplicaron el riesgo de no adhesión— y 
autoevaluación de la manera como se sigue el tratamiento —excelente 
o buena aumentó cinco veces la probabilidad de adhesión—. 
Conclusión. La depresión y la autoevaluación del cumplimiento 
se asociaron con adhesión al tratamiento antirretroviral. Se sugiere 
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profundizar el estudio de la percepción de apoyo social y variables 
cognitivas, como la autoeficacia y percepción de riesgo, en personas 
que viven con VIH/sida.
Palabras clave: VIH; Terapia antirretroviral altamente activa; Adhesión 
al tratamiento; Depresión; Ansiedad; Apoyo social (DeCS).
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Introduction
HIV is a public health concern worldwide. Since 2000, 38.1 million 
people have acquired the virus and 25.3 million have died from AIDS-
related illnesses (1). In 2015, UNAIDS (2) reported an average of 34 to 
39.8 million people living with HIV/AIDS (PLWHA) in the world; in 
Latin America, the figure ranges between 1.7 and 2.3 million. According 
to the same report, 17 million people had access to antiretroviral therapy 
(ART) in December 2015, while about 22 million people did not have 
access to treatment at all. About 28 million new cases could be avoided, 
if response to AIDS in low- and middle-income countries increases (3). 
The Colombian Public Health Surveillance System reported 8 
196 new PLWHA cases in 2012 (4), with the highest incidence in 
Barranquilla (50.6 cases per 100 000 inhabitants), Quindío (28.4 
cases per 100 000 inhabitants), and Cartagena (37.6 cases per 100 000 
inhabitants). In addition, 2 216 deaths associated with HIV/AIDS and 
a mortality rate of 4.76 per 100 000 inhabitants were reported. Quindío 
was one of the most affected departments by this epidemic (5). 
HIV/AIDS is considered a chronic disease that involves multiple 
factors, since it has an impact on physical and mental functioning 
(6) and may affect self-concept and sense of life (7). This condition 
is a stressor that implicates psychological, physiological, social 
and economic aspects, therefore, it demands strategies that favor 
treatment and reduce threats to health. In this regard, the patient’s 
attitudes and coping techniques can influence the HIV infection 
process (8), which, in turn, demands changes in lifestyle to comply 
with therapeutic indications. This is known as adherence to treatment, 
and indicates the commitment and participation of the individual 
in self-care (9,10).
Although no consensus in the definition of treatment adherence has 
been achieved (also known as cooperation or therapeutic compliance), 
it is generally understood as a complex and multifactorial problem 
that transcends following closely medical instructions or prescriptions 
(9,11). As proposed by DiMatteo & DiNicola, and accepted by other 
researchers, adherence is an active process of voluntary collaboration 
established between the patient and the health personnel to carry out 
mutually agreed upon behaviors, in order to generate the desired 
therapeutic effect (10,12,13). 
Piña-López & Sánchez-Sosa (14) suggest that adherence in 
PLWHA is determined by the frequency with which subjects develop 
behaviors to comply with the instructions provided by health personnel 
based on their own skills. Adherence behaviors are a consequence of 
the interaction between biological variables (HIV disease and other 
conditions) and psychological variables (interaction styles related to 
stress, abilities, motives and emotional states), which have effects on 
health, control and course of infection with HIV (11,14).
Different situations may affect adherence to treatment in chronic 
diseases, for example, the nature of the disease, the time of evolution, 
the expectation of treatment outcomes, the characteristics of the 
treatment, the habits and customs of the patient (15,16), the interaction 
with health professionals, the characteristics of the health institution (9), 
and psychological and social aspects such as coping strategies (6). Other 
important factors in HIV infection include its asymptomatic character 
in most cases, the amount of drugs supplied (antiretrovirals and those 
necessary for opportunistic diseases), social stigmatization, side effects 
of certain drugs, patient’s beliefs, affective states, perception of control 
over stressful life events, and the disease, among others (17,18). 
Following the model of Sánchez-Sosa et al. (19), psychological 
variables such as depression, stress, anxiety, low motivation and lack 
of social support can contribute to the progression of the disease and 
reduce the quality of life of the affected patients.
Remor (20) reports low adherence in the presence of high levels of 
anxiety, stress, depression and poor social support. Piña-López et al. 
(21) and Piña-López et al. (22) report competencies, stress, motives, 
frustration, tolerance and ambiguity as predictors of adherence, which 
may vary according to the time of infection; also, Piña-López et al. 
(23) proposed that intermediate levels of stress and low levels of 
depression are favorable, and, finally, Piña-López et al. (24) add 
that associated psychological variables are affected by self-report 
on social competences. 
Arrivillaga et al. have identified a correlation between anxiety and 
depression, as well as a perception of poor control over health and 
stressful life events in women living with HIV/AIDS, which affect their 
adherence and quality of life. Likewise, Arrivillaga et al. (26), Arrivillaga 
et al. (27) y Arrivillaga et al. (28) stress the role played by social and 
economic factors in the adherence to antiretroviral treatment (ART) 
by women. Social support is another key factor associated with better 
health results, adherence and quality of life in PLWHA (7,25,29-31).
In this regard, adherence to ART is a complex process, permeated 
by psychological and social factors of great relevance for the 
evolution, treatment and quality of life of PLWHA. These factors 
need to be further analyzed given the implications for public health 
that the lack of adherence to ART have, and to contribute to the 
enrichment of intervention programs. It is, therefore, pertinent to 
generate knowledge in this field, and specifically in one of the leading 
departments of morbidity and mortality caused by HIV/AIDS in 
Colombia. The aim of this study was to establish the association 
between adherence to antiretroviral therapy and depression, anxiety, 
perception of social support and sociodemographic variables in a 
group of PLWHA in Quindío, Colombia during 2015.
Methodology
This is an observational and analytical cross-sectional study, in 
which 70 PLWHA participated —men and women enrolled in an 
accompaniment program offered by a health institution in Quindío 
(Colombia). Some of them were hospitalized and others were 
attending medical and psychological follow-ups. Sampling was non-
probabilistic, intentional, and selected taking into account as inclusion 
criteria HIV diagnosis, ART, being of legal age, no physical or mental 
conditions that would hinder understanding the instruments, will to 
participate in the study, and a signed informed consent. 
A socio-demographic data survey was used for collecting 
information regarding age, sex, marital status, schooling, 
socioeconomic stratum and religion. In addition, variables related 
to the disease such as diagnosis time, perception of family support 
and understanding during the treatment, consumption of psychoactive 
substances (cigarettes, coca paste and/or marihuana), frequency of 
psychological therapy, and self-report on how treatment was followed 
were also investigated.
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Adherence to ART was assessed using the Morisky-Green Scale 
(32), which reflects patient compliance with medication and has 
been used in different studies (33-36). This instrument consists of 
four questions with two response options (Yes/No); if the answer for 
any of these items is Yes, it means that the patient has failed and is 
reported as non-adherent. 
To identify depressive symptoms and their severity, the Beck 
Depression Inventory (BDI) was applied; this is a 21-item scale that 
considers psychological-cognitive and somatic-vegetative aspects, which 
are evaluated based on affirmations selected by the individual. The scores 
range from 0 to 3, yielding a total number between 0 and 63. A score of 0 
to 9 indicates absence of depression; 10 to 18, mild depression; 19 to 29, 
moderate depression, and from 30 onwards, severe depression (37,38).
On the other hand, the Beck Anxiety Inventory (BAI) was 
used to evaluate anxiety symptoms when investigating subjective, 
neurophysiological, autonomic and panic factors. This inventory is 
made up of 21 items, each with the following response options:  0-not 
at all; 1-slightly, it does not bother me much; 2-moderately, it was very 
unpleasant but I could bear it, and 3-severely, I could hardly bear it. In 
the Spanish version, the cut-off points are 0 to 7 for minimal anxiety, 
8 to 15 for mild anxiety, 16 to 25 for moderate anxiety, and 26 to 63 
for severe anxiety (39).
Perceived social support was assessed using the Medical Outcomes 
Study (MOS) questionnaire designed by Sherbourne and Stewart in 1991, 
and adapted to the Colombian population (40), which assesses structural 
support or size of the social network (item 1) and functional support 
(perception of support, items 2-19). Functional support is independent 
and multidimensional, and is composed of emotional/informative, 
tangible and affective social support and positive social interaction. 
The first question inquiries into the number of close friends and relatives. 
The remaining questions have answering options from 1 to 5 (never, 
rarely, sometimes, most of the time, always). The raw scores range from 
19 to 95, and a higher score indicates greater perceived social support. 
The study was supported by the Bioethics Committee of the 
Universidad de San Buenaventura Medellín. The instruments were 
codified and a route was established for channeling severe depression 
and anxiety cases or suicidal ideation in order to refer patients to 
specialists or appropriate care centers. Subsequently, the participants 
were contacted to be informed about the objectives and procedures 
of the study, and to request voluntary participation. An appointment 
was coordinated with those who accepted under certain conditions 
to ensure confidentiality. 
The instruments were applied through an individual interview; 
prior informed consent was signed and participants were informed 
about the purpose of the study, voluntariness, confidentiality and 
non-remuneration, as well as about their right to abandon the study 
at any time. Individual results were returned to participants, and 
general results to the health institution. Lastly, the channeling route 
was activated in the necessary cases.
Data tabulation was performed in Microsoft Excel 2013, and the 
statistical analysis was made through SPSS version 21. Univariate 
and bivariate analyzes were performed. Central tendency, dispersion 
and position were evaluated as quantitative variables and, on the other 
hand, qualitative variables included absolute and relative frequencies. 
To determine the existence or non-existence of statistical association, 
the odds ratio (OR) was calculated and its confidence intervals and p 
values were deemed as significant when they were <0.05. 
It should be noted that depression and anxiety variables were 
dichotomized for the analysis, and were reported as absent/mild 
depression, moderate/severe depression, and minimal/mild anxiety, 
moderate/severe anxiety. Regarding social support perception, the 
scores found in the first three quartiles were taken as low, and the 
ones in the last quartile were considered high. The socioeconomic 
stratum variable was analyzed based on the Colombian stratification, 
and was grouped into three categories: 0, 1 and 2, which included 
homeless population, low-low and low strata, and 3, 4 and 5 strata 
gathering middle-low, medium and medium-high strata.
Results
70 people, aged between 18 and 66 years, answered the survey; the 
average age was 38, with a standard deviation of 12 years. The highest 
age in 50% of the participants was 38, and the most frequent was 28. 
The highest proportions were found among men (64.5%), patients 
of socioeconomic strata 0, 1 and 2 (82.3%), catholics or protestants 
(82.9%), high school graduates (43.9%), and single (44.9%). 38.2% of 
the subjects were diagnosed two years or less before they participated 
in the study. Most of them (71.4%) reported feeling supported and 
understood by their relatives, and affirmed that they were receiving 
psychological therapy on a regular basis. 30% of the patients reported 
that they are currently using psychoactive substances.
57.1% of the patients did not show adherence to the pharmacological 
treatment, although most of them state that they are following it with 
excellent outcomes (74.2%). Regarding the psychological variables, 
absent or mild levels of depression were found in most participants; 
30% scored moderate or severe depression. Moderate or severe levels 
of anxiety were observed in 28.6% of the cases, and the perception 
of little social support in 77.1% (Table 1). 
Bivariate analysis
In order to determine some associations that would indicate possible 
factors related to ART adherence, a bivariate analysis was performed. 
Two of the evaluated variables had a statistically significant association 
with adherence: self-report on the way in which treatment was 
followed (p=0.038, OR=5.385, 95%CI: 1.096-26.46) and depression 
(p=0.040, OR=3.33; 95%CI: 1.056-10.52). The p-value found in 
the remaining variables was >0.05, although a higher proportion of 
adherence was observed in women, in people from socioeconomic 
strata 3 to 5, in those who have more than 10 years of diagnosis, in 
those who do not profess any religion, are married or in some kind of 
relationship, have technical or professional studies, who frequently 
or always feel support and understanding from their families, those 
who attend therapy periodically, who are not currently using any type 
of illegal substance, and those who have low levels of anxiety and 
perceive high levels of social support (Table 2).
Discussion
This study identified adherence to treatment in a group of PLWHA in 
Quindío and its association with psychological and social variables that 
may play a fundamental role in interventions with this population. An 
outstanding percentage of subjects showed poor adherence (57.1%), 
which is highly relevant since this situation may indicate how patients 
are coping with their condition and, at the same time, how their quality 
of life and their relatives or closed ones are being affected by it.
Lack of adherence to long-term treatment leads to personal, social, 
health and economic issues, as it generates a greater risk to health 
(relapses, onset or worsening of symptoms, evolution to late or severe 
phases of the disease, adverse effects, and resistance to medication), 
lower quality of life and well-being; higher rates of stress, interference 
with lifestyle or alterations in performance areas of patients and their 
relatives, and greater probability of increasing the demand for hospital 
and pharmaceutical resources (41).
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Table 1. Percentage distribution of sociodemographic, family, health and 




n % n % n %
Socioeconomic strata
0, 1 y 2 31 77.5 20 90.9 51 82.3





36 81.8 22 84.6 58 82.9
Non-believer/other 8 18.2 4 15.4 12 17.1
Education
Fifth grade 14 35 11 42.3 25 37.9
Complete High 
school
17 42.5 12 46.2 29 43.9
Professional or 
technical studies
9 22.5 3 11.5 12 18.2
Civil status
Married, domestic 
partnership, in a 
relationship
14 31.8 11 44 25 36.2
Single 23 52.3 8 32 31 44.9
Separated/Widowed 7 15.9 6 24 13 18.8
HIV diagnosis
≤2 years 19 44.2 7 28 26 38.2
3-5 years 8 18.6 3 12 11 16.2
6-10 years 9 20.9 6 24 15 22.1





Never/sometimes 4 9.1 4 15.4 8 11.4
Many times/always 32 72.7 18 69.2 50 71.4
They do not know 
about the diagnosis
8 18.2 4 15.4 12 17.2
Frequency of 
psychology counseling
Weekly or monthly 13 46.4 12 57.1 25 51
Bimonthly, quarterly, 
other
15 53.6 9 42.9 24 49
Self-report on how 
treatment is followed
Excellent or good 28 75.7 18 72 46 74.2




coca paste and/or 
marihuana)
Yes 17 38.6 4 15.4 21 30
No 27 61.4 22 84.6 49 70
Adherence to treatment
No 26 65 14 35 40 57.1
Yes 18 60 12 40 30 42.9
Depression
Absent/Mild 29 65.9 20 76.9 49 70
Moderate/Severe 15 34.1 6 23.1 21 30
Anxiety
Minimal/Mild 30 68.2 20 76.9 50 71.4
Moderate/Severe 14 31.8 6 23.1 20 28.6
Perceived social support
Low 37 84.1 17 65.4 54 77.1
High 7 15.9 9 34.6 16 22.9
Source: Own elaboration based on the data obtained in the study.
With this in mind, a public health problem is surfacing and demanding 
more attention, especially when it comes to low adherence to ART due 
to an increased probability of risk behaviors and possible reinfection 
and resistance to treatment, both in patients who have already been 
treated as in those who are just initiating a therapeutic regimen but have 
contracted a resistant virus (17,20). In addition, it causes a decrease in 
lymphocyte count and an increase in viral load, which facilitates the 
appearance of opportunistic diseases (21).
The findings in PLWHA from Quindío are not far removed 
from research in the field of adherence to treatment in Colombia, 
where Arrivillaga et al. (26) have indicated approximate figures 
(43%). In other countries, around 50% of patients with chronic 
diseases adhere, although this number can be between 37% and 
83% in patients with HIV depending on the type of medication and 
population (42). Some studies show that about 50% of PLWHA 
fail to comply with medication intake and schedules, while 14% 
continue to maintain the risky behaviors that led them to become 
infected (17,43,44). It should be noted that adherence decreases as 
the complexity of the treatment increases, and that ART demands 
high compliance from the individual (more than 90-95%) to avoid 
resistance (21,45). 
42.9% of patients in this study report being adherent. When 
comparing these results with other works, approximate figures can 
be found: in Spain reported adherence is 55% (45), in Venezuela 
63.2% (46), and in Mexico between 31.9% (31), 57% (22), 65.6% 
(23) and 85.3%. This last indicator was not common when compared 
to most findings reporting a figure of about 50%, which may be 
explained by factors such as motivation and stress (19), particularly 
in Los Angeles, where the value reaches 63% (47).
However, differences with other studies were found: a study 
carried out in Madrid did not achieve strict therapeutic compliance 
not even in the third of the patients evaluated (20). In contrast, a 
longitudinal study in Italy reported a total of 81.4% of adherent 
patients (48). Comparative studies could help to reveal the contextual 
factors related to these differences. 
Moreover, this research shows statistically significant differences 
that indicate greater adherence in those whose self-report is excellent 
when asked about the way they are following their treatment. 
However, despite the fact that 74.2% of PLWHA say that they have a 
good or excellent compliance with the treatment, only 42.9% adhered 
adequately according to the measurement instrument. The relevance 
of this aspect lies in the role of cognitive variables such as self-
efficacy, locus of control, health beliefs, perception of vulnerability 
and treatment effectiveness in adherence behaviors (9-11), which 
require further research.
Similarly, there is a significant association between treatment 
adherence and depression. When depressive symptoms are absent or 
mild, the proportion of adherent and non-adherent patients does not 
differ. However, when these symptoms are moderate or severe, there 
is a significant difference, which indicates a greater probability of 
adherence among those with lower symptomatology. These findings 
coincide with reports in other countries such as Spain (20), Mexico 
(23) and Chile (49). 
This situation is likely to be caused by the fact that HIV diagnosis 
and treatment generate distress (50), emotional alterations related to 
mourning due to the loss of health, and the assumption of a new role 
as a PLWHA, which can be more evident than in other diseases (e.g. 
cancer) (51). Likewise, patients may face discrimination and affective 
or economic losses given the social stigma that comes along with 
the disease, which in turn could generate alterations in their mood 
(12); furthermore, depressive symptoms may be a side effect of some 
transcriptase inhibitors (52,53). 
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Table 2. Association between sociodemographic, family, health and psychological variables, and adherence to treatment in people 







n % n %
Sex
Men 18 40.9 26 59.1 - 1.000 - -
Women 12 46.2 14 53.8 0.669 1.238 0.466 3.291
Socioeconomic strata
0, 1 and 2 23 45.1 28 54.9 - 1.000 - -




22 37.9 36 62.1 - 1.000 - -
Non-believer/Other 8 66.7 4 33.3 0.077 3.273 0.881 12.156
Education
Fifth grade 10 40 15 60 - 1.000 - -
Complete High school 11 37.9 18 62.1 0.876 0.917 0.306 2.745
Professional or technical 
studies
8 66.7 4 33.3 0.136 3.000 0.709 12.694
Civil status
Married, domestic 
partnership, in a 
relationship
13 52 12 48 0.430 1.733 0.443 6.789
Single 11 35.5 20 64.5 0.851 0.880 0.231 3.353
Separated/Widowed 5 38.5 8 61.5 - 1.000 - -
HIV diagnosis
≤2 years 10 38.5 16 61.5 - 1.000 - -
3-5 years 5 45.5 6 54.5 0.692 1.333 0.320 5.548
6-10 years 6 40 9 60 0.923 1.067 0.291 3.916





Never/sometimes 3 37.5 5 62.5 0.848 1.200 0.185 7.770
Many times/always 23 46 27 54 0.430 1.704 0.454 6.396
They do not know about the 
diagnosis
4 33.3 8 66.7 - 1.000 - -
Frequency of 
psychology counseling
Weekly or monthly 11 44 14 56 - 1.000 - -
Bimonthly, quarterly, other 13 54.2 11 45.8 0.477 1.504 0.488 4.639
Self-report of how 
treatment is followed
Excellent or good 20 43.5 26 56.5 0.038 * 5.385 1.096 26.462




coca paste and/or 
marihuana)
Yes 8 38.1 13 61.9 - 1.000 - -
No 22 44.9 27 55.1 0.599 1.324 0.466 3.766
Depression
Absent/Mild 25 51 24 49 0.040 * 3.333 1.056 10.525
Moderate/Severe 5 23.8 16 76.2 - 1.000 - -
Anxiety
Minimal/Mild 23 46 27 54 0.403 1.582 0.540 4.631
Moderate/Severe 7 35 13 65 - - -
Perceived social 
support
Low 20 37 34 63 - 1.000 - -
High 10 62.5 6 37.5 0.077 2.833 0.894 8.975
* Statistically significant differences (p<0.05). 
Source: Own elaboration based on the data obtained in the study.
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The role of depression is fundamental to treatment, since negative 
thinking compromises the behavioral activity of those who present it 
at moderate and severe levels. Also, evidence shows that emotional 
states influence the functioning of the immune system and the 
evolution of HIV infection, particularly distress, depression and 
anxiety (18,44,54-56). The latter is identified in a higher proportion 
among non-adherents at moderate or severe levels, although no 
statistically significant differences have been observed. 
Additionally, a higher proportion of adherence was found among 
those who scored higher in social support, even though no statistically 
significant differences were observed. This aspect has been studied 
extensively and is considered a factor that favors ART due to its 
buffering effect against stressful situations and depressive symptoms 
and, in general, its contribution to the process of adaptation to the 
new lifestyle. 
There are many studies around the world that show social support 
as a protective factor related to adherence, well-being, perceived 
health and quality of life of PLWHA (18,29,31,57-59). This positive 
effect has also been confirmed in Colombia (7), where the search for 
professional support (6) and participation in support groups are also 
included (27). Similarly, the relationship between poor adherence 
to treatment, higher rates of emotional disturbances (distress and 
depression) and poor social support are clear (8,20,21,44); in spite 
of this, the fact that it can also become a source of conflict and stress 
must not be ignored (18).
In this particular sample, it is striking that when applying the 
MOS inventory, most participants perceived they were not socially 
supported, which is important for intervention in this context; 
however, when asked if they feel supported and understood by their 
relatives in relation to the treatment, most reported feeling it many 
times or always. This difference might suggest that, at first sight, 
although patients refer feeling supported, the way they receive such 
support is not perceived from an instrumental, affective, emotional 
or informational perspective in their daily lives, as the test indicates. 
Further studies are required on what it means to provide and 
receive support, and to take a closer look at the different subtypes 
and their relationship to adherence. Likewise, it is important to 
delve into the role of social stigmatization, which can act to the 
detriment of seeking support, communicating the diagnosis, and 
deploying skills to obtain emotional and material support available 
in the surrounding environment.
Other results of this study indicate greater proportions of adherence 
in women (although not statistically significant), which requires more 
comparative research, and also among those who have higher levels 
of schooling and socioeconomic stratum, which is similar to the 
findings in other studies (26,60). Moreover, high adherence was also 
found in those who have a longer time of diagnosis, which positively 
interacts with the psychological variables that affect adherence (22), 
although its effects are inconclusive. In this regard, Levine et al. 
(47) observed that adherence seems to decline over time and Remor 
(20) identified greater adherence in patients with shorter infection 
times, since an increase in the probability of poor adherence when 
treatments involve several drugs for an indefinite period of time was 
observed. Finally, adherence was better in those who did not consume 
psychoactive substances, which is consistent with the literature 
presenting consumption as a problem in PLWHA (44,47). As for 
religion, studies are needed to elucidate its role as a coping strategy.
However, psychological and personal factors are not the only 
aspects implicated in adherence, since their effect may be influenced 
or mediated by aspects concerning the disease (symptoms and 
characteristics), treatment (secondary symptoms, therapeutic 
efficacy, doses, schedules, method of administration), the health 
system (characteristics of the system, barriers to medical care and 
accessibility to social and pharmaceutical services), the interaction of 
the patient with the health care team (relationship, communication, 
satisfaction, active involvement of staff and confidentiality) or social 
circumstances (educational level, social position, geographical 
and economic conditions, stigma and discrimination) (9,13,15,60-
62). These aspects exceeded the objectives of this study, but the 
need for more research in this respect is emphasized to strengthen 
explanatory models.
In this sense, it is worth noting that research and work on adherence 
from a biopsychosocial perspective that considers all kinds of barriers 
and facilitators have a key role, so that people can exercise their 
duties and rights in health and follow their treatments adequately, 
particularly in developing countries (63). In Colombia, Arrivillaga et 
al. (26), Arrivillaga et al. (27), Arrivillaga et al. (28), and Arrivillaga 
et al. (62) report that the role of the health system, the socioeconomic 
position, gender role and other social aspects are some of the main 
obstacles to adherence to ART.
Finally, it is necessary to be cautious when interpreting the findings 
of this study due to the type and size of the sample and to the absence 
of validation measures in the Colombian population.
Conclusions
A high percentage of PLWHA did not report adequate adherence 
to ART (57.1%). A statistically significant association was found 
between adherence and depressive symptoms and self-assessment 
on the way treatment was followed. Low anxiety and high 
perception of social support did not represent statistically significant 
differences, but indicated higher proportions between adherents. 
The findings are related to global trends and some Colombian 
studies. There are no conclusive results on the association between 
diagnostic time, sociodemographic variables and adherence 
to treatment.
Research on this topic has not discriminated some physiological 
symptoms that are typical of the infection, and those provoked by 
mood disorders; in addition, knowing the mental health history of 
the patients influences manifestation and coping methods, and would 
require further research on mediating variables and moderators of 
the relationship between depression and adherence. 
In conclusion, longitudinal and mixed studies are recommended, as 
well as model proposals that include the analysis of the role of social 
and health barriers in adherence. The validation of interdisciplinary 
intervention programs contextualized to each region is pertinent in 
order to give effective answers to this situation that compromises 
public health.
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